Tzu-Ling (Karen) Tseng

Dr. Tseng founded Bio Preventive Medicine Corp. (BPM) with more than 25 years of biomedical research experiences and leadership in Taiwan and US. BPM is an innovative and clinical-staged biotech company, focusing on developing novel biomarker-based diagnostic products. She previously served as Head of a National Biomarker Research Program and Deputy General Director of Biotech and Pharmaceutical Research Laboratories at ITRI, which is a national institute in Taiwan and listed as one of the Top 100 Global Innovators.  She has started developing biomarkers since she worked at National Cancer Institute, NIH, in US. Dr. Tseng received her doctoral fellowship training in molecular biology at Cold Spring Harbor Laboratory, NY (ranked No. 1 in the world for its impact in molecular biology and genetics) and a Ph.D. in Genetics from the State University of New York at Stony Brook in New York, US. She is the inventor of a series patents in biomarker area, including biomarkers for detecting renal disease, auto-immune disease, liver fibrosis and cancer with more than 100 issued patents.